(NASDAQ: CRSP) Crispr Therapeutics Ag's forecast annual revenue growth rate of 433.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 46.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 22.19%.
Crispr Therapeutics Ag's revenue in 2026 is $3,510,000.On average, 30 Wall Street analysts forecast CRSP's revenue for 2026 to be $5,738,193,922, with the lowest CRSP revenue forecast at $0, and the highest CRSP revenue forecast at $25,270,053,090. On average, 24 Wall Street analysts forecast CRSP's revenue for 2027 to be $10,256,990,440, with the lowest CRSP revenue forecast at $0, and the highest CRSP revenue forecast at $25,347,801,193.
In 2028, CRSP is forecast to generate $64,088,432,969 in revenue, with the lowest revenue forecast at $7,619,314,067 and the highest revenue forecast at $388,260,587,040.